A pièce de resistance: how HIV-1 escapes small molecule CCR5... : Current Opinion in HIV
and AIDS A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors : Current …

Unlike HIV-1 and simian immunodeficiency virus (SIV), which induce a slow, unrelenting
loss of immune function spanning several years, highly pathogenic simian–human …

Early human immunodeficiency virus infection is characterized by the predominance of
CCR5-tropic (R5) virus. However, in many individuals CXCR4-tropic (X4) virus appears in …

Maraviroc (MVC) is a CCR5 antagonist that inhibits HIV-1 entry by binding to the coreceptor
and inducing structural alterations in the extracellular loops. In this study, we isolated MVC …

The emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants is
associated with accelerated disease progression. CXCR4-using variants are believed to …

To date, most therapeutic and vaccine candidates for human immunodeficiency virus type 1
(HIV-1) are evaluated preclinically for efficacy against cell-free viral challenges. However …

The identification of surfactant protein A (SP-A) as an important innate immune factor of the
lungs, amniotic fluid, and the vaginal tract suggests that it could play an important role during …

ABSTRACT HIV-1 infection is mediated by a viral envelope subsequently binding to CD4
receptor and two main coreceptors, CCR5 (R5) for primary infection and CXCR4 (X4) in …

CXCR4 coreceptor usage appears to occur less frequently among HIV-1 subtype C viruses.
The aim of this study was to investigate the genetic determinants within the V3 region of …

Since the identification of CCR5 and CXCR4 as HIV coreceptors a little over a decade ago,
there has been hope that coreceptor inhibitors will be able to make an impact on the HIV …